Lorenzo Canova

Gastroenterologist and Hepatologist.
Liver enthusiast, mountain lover and rookie guitarist.

[The Baveno Cooperation: an EASL Consortium @BavenoCoop]

It’s finally here‼️

🎉 Baveno VIII has arrived — just in time for some good summer reading ☀️📖

Time to dive into the latest consensus on portal hypertension from @BavenoCoop

Enjoy! 😉

🔗 https://t.co/cZSckSc3zk

[Hong Jae Chon @hongjaechon]

❓ Can we predict hepatic decompensation in unresectable HCC patients receiving Ate/Bev? @AmerGastroAssn
👉 The ARTE score (nPVT, bilirubin ≥2 mg/dL, platelets ≤100×10³/mm³) stratifies decompensation-free survival at 87% vs 79% vs 57% at 12 months for low/intermediate/high-risk groups (HR 4.28, p<0.001).
👉 Retrospective multicenter study by Canova et al. has recently been published in Clinical Gastroenterology and Hepatology.
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE Score
DOI: https://t.co/6TpChNNrnl
@ILCAnews @EASLnews @myESMO @AACR @ASCO 
#HCC #Unresectable #ARTE #Decompensation

[Lorenza Rimassa @LorenzaRimassa]

Standing ovation for RASOLUTE-302 of #daraxonrasib in second-line #PDAC at #ASCO26 plenary session. Finally a practice changing trial for patients with advanced PDAC. Now we need daraxonrasib in clinical practice soon! @ASCO

[The Baveno Cooperation: an EASL Consortium @BavenoCoop]

🧫 CKD predicts worse outcomes after TIPS for ascites
🗣️ @luistevilla | #EASLCongress

Key results (EuroTIPS cohort, n=653):
🔬 CKD → ↑ mortality (aHR 2.26) &amp; ↑ persistent ascites (aRR 3.35)
⚠️ MASH+CKD = extreme risk: aRR 7.06!
💡 Screen for CKD before TIPS

[The Baveno Cooperation: an EASL Consortium @BavenoCoop]

📜 Anticoagulation for PVT in cirrhosis
🗣️ N. Riva |
💡 Treat based on: LT candidacy, thrombus extension &amp; cirrhosis severity
🔬 DOACs in cirrhosis:
✅ Child A → all DOACs OK
⚠️ Child B → apixaban/edoxaban with caution, avoid rivaroxaban
❌ Child C → avoid all DOACs

[massimo iavarone @massimoiava]

It's fantastic to see young members of the group grow up, presenting their abstract at @EASLnews congress (this format is brilliant!), and having their paper accepted and published @AGA_CGH the very same day! @LaStatale @policlinicoMI @Bernd_Schnabl #HCC

[Lorenzo Canova @Lcanova94]

Today I got to present at @EASLedu Congress the results of our ARTE-score for the prediction of hepatic decompensation in uHCC under AB. Thanks to Francesco Tovoli and @DJPinato for making all this possible and a special thanks to my mentor @massimoiava
https://t.co/Ptx5mw87h8

[Hong Jae Chon @hongjaechon]

❓ Should hepatic decompensation be included as a formal endpoint in advanced HCC clinical trials? @ElsevierConnect
👉 Yes — it carries an ~8× higher hazard of death than radiologic progression alone, yet remains a missing endpoint in current trials.  
👉 Review by Cabibbo et al. has recently been published in Cancer Letters.

Hepatic decompensation: A missing endpoint in advanced hepatocellular carcinoma trials  
DOI: https://t.co/vPyLOUR4Gs

@ILCAnews @EASLnews @myESMO @AACR @ASCO 
#HCC #HepaticDecompensation #LiverCancer #ClinicalTrials #TrialDesign

[Elliot Tapper @ebtapper]

Love this paper
1. Checking ANA in everyone with elevated ALT is unhelpful, sometimes harmful, usually confusing
2. Biopsy when ALT &lt;100 but ANA elevated is not useful
3. Autoimmune hepatitis is a clinical diagnosis and frequently made DESPITE biopsy findings

[The Baveno Cooperation: an EASL Consortium @BavenoCoop]

⏳ Final countdown: 3 weeks to #BavenoVIII‼️

9⃣ expert panels across the full PH spectrum — from risk stratification in cACLD to decompensation prevention/management, bleeding, recompensation &amp; vascular liver disorders
🗓️ 27-28 March-🧒29/03
🔗 https://t.co/5tL0wP7mQF
📄 👇

[Arndt Vogel @ArndtVogel]

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study
@HEP_Journal
👉538 pts 🇮🇹
👉mOS 19.7 mo, 36-month survival rate 30.0%
👉4.4% drug-free disease-free
👉14.1% liver decompensation
@myESMO @ASCO @EASLnews @ILCAnews

[massimo iavarone @massimoiava]

This year's @EASLnews Liver Cancer Summit was a truly fantastic event! It was useful for learning, listening to young researchers who are projecting us into the future, networking, strengthening friendships. See you in Barcelona! EASL 2026 Annual Congress https://t.co/XnG4cMHAlI

[Lorenzo Canova @Lcanova94]

Looking for a tool to help you characterise patients at higher risk of HCC early recurrence after LR treatment? This might be a promising start! #ASAP #HCC
Thanks to @massimoiava for being the mentor he is.
https://t.co/1CuF5LTeqJ

[Thomas Reiberger @ReibergerThomas]

Treatment response to #bulevirtide is linked to amelioration of #PortalHypertension in patients with chronic #HepatitisD

@JHEP_Reports
🔗https://t.co/e1J9wTlvBd

[JHEP Reports @JHEP_Reports]

🟣Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis

🔓#OpenAccess at👉https://t.co/dUPDRL5gI0

#LiverTwitter #LiverX #AutoimmuneHepatitis
@macarlotal

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
Camrelizumab plus rivoceranib vs sorafenib as 1st line therapy for HCC
@TheLancetOncol
https://t.co/1zHz657RBY
🔎CARES-310 final analysis
👉mOS: 23·8 vs 15·2 mo
👉mPFS: 5·6 vs 3·7 mo
🧐Many positive phase-2 and -3 study with this combo, form peri-operative to advanced
@myESMO @EASLedu @ILCAnews

[Lorenzo Canova @Lcanova94]

It has been an amazing ride! My 4 years of residency have come to an end. I have met and learnt from so many amazing people during these years. Thank you, now off to a new adventure.

[Beatriz Gros @Bealoquebea]

🚨Doctors in Spain are striking.
Why? Because our working conditions are unsustainable

🔹 Our base salary is ~€1,300/month. The rest comes from on-calls or “continuity shifts”, meaning we only earn a decent wage by working excessive hours often exceeding 60-70h/week
🔹on-calls are 24h shifts, without rest, often several per month. These hours do not count for retirement
🔹 Many doctors leave the country, not because of lack of vocation, but because it is impossible to build a dignified and safe career under these conditions
🔹plus most of the research is done in your free time and for free

This is not just about doctors only it’s about patient safety and the future of healthcare in Spain

[Arndt Vogel @ArndtVogel]

🔥now fully published:
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
@JHepatology
https://t.co/wrmzv3agRm
✅"long-term" survival in HCC, we are getting there
@myESMO @EASLedu @ILCAnews

[Thomas Reiberger @ReibergerThomas]

@BavenoCoop @EASLnews @AASLDtweets

At any given #HVPG spleen stiffness #SSM was higher in 🍔#MASLD than in 🍷#ALD cirrhosis

Suggesting a ⏮️PREsinusoidal #PortaHypertension component in #MASLD

📕@LiverInt study by our #Liver team @MedUni_Wien
🔗https://t.co/XUZlFtK3lI